Editor and Moderator			Faculty
	Neil Love, MD Medical Oncologist Editor Breast Cancer Update for Surgeons Research To Practice Miami, Florida		J Michael Dixon, MD Consultant Surgeon and Senior Lecturer Academic Office Edinburgh Breast Unit Western General Hospital Edinburgh, United Kingdom Mark D Pegram, MD Director for Translational Research Program Braman Family Breast Cancer Research Institute UM Sylvester Comprehensive Cancer Center Miami, Florida Peter M Ravdin, MD, PhD Research Professor of Biostatistics The University of Texas MD Anderson Cancer Center Houston, Texas
Co-Chair
	Pat W Whitworth Jr, MD Director, Nashville Breast Center Clinical Associate Professor of Surgery Vanderbilt University Nashville, Tennessee

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Dixon had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Pegram — Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Pfizer Inc; Speakers Bureau: Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis. Dr Ravdin — Consulting Agreement: Genomic Health Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP; Stock Ownership: Adjuvant! Inc, Bristol-Myers Squibb Company, Pfizer Inc, Wyeth. Dr Whitworth — Advisory Committee, Consulting Agreements and Speakers Bureau: Genomic Health Inc, Novartis Pharmaceuticals Corporation; Paid Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

---

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Table of Contents

Top of Page

Home | Search

Editor's Note
State of the art 2008
Neil Love, MD

Slides and Faculty Comments

Sentinel Lymph Node Biospy (LSNB) Relative to Neoadjuvant Systemic Therapy

Neoadjuvant Systemic Therapy

Sentinel Node Biopsy Injection Site

Partial Breast Irradiation (PBI)

Genomic Assays: Prediction of Benefit from Chemotherapy

Hormone Receptor-Positive Breast Cancer

Assessment of Her2 Status

- Select Publications

A CME Audio Series and Activity

Faculty Disclosures

Editor's Office